Shima Kalantarifard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shima Kalantarifard has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Abolfazl Heydari
Polymer Institute of the Slovak Academy of Sciences, Dúbravská cesta 9, 845 41, Bratislava, Slovakia
1 shared publication - Ahmed Mohamed Omer
Polymer Institute of the Slovak Academy of Sciences
1 shared publication - Forough Rasoulian
Center for Regenerative Medicine, University of Continuing Education Krems, 3500, Krems, Austria
1 shared publication - Igor Lacík
Polymer Institute of the Slovak Academy of Sciences Dúbravská cesta 9
1 shared publication - Juraj Filo
Department of Organic Chemistry, Faculty of Natural Sciences, Comenius University, Ilkovičova 6, Bratislava, Slovakia, SK-842 15
1 shared publication - Lucy Vojtová
Advanced Biomaterials Group, Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, 612 00 Brno, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 21 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Cyclodextrin-epichlorohydrin-cyanoguanidine polymer for resveratrol delivery to enhance human chondrocyte function in cartilage repair
Water-soluble β-cyclodextrin-epichlorohydrin polymers (CDP) are widely utilized for molecular encapsulation, drug delivery, and regenerative medicine. In this work, we present the synthesis of a novel polymer of this family, β-cyclodextrin-epichlorohydrin-cyanoguanidine polymer (CDPC). The primary objective was to evaluate its potential as an efficient carrier for the encapsulation of resveratrol (RES), with a particular focus on applications in cartilage repair. CDPC was synthesized by reacting β-cyclodextrin (β-CD) with epichlorohydrin in the presence of cyanoguanidine (CyG), a nitrogen-rich compound that remains non-protonated under physiological pH. The incorporation of CyG into the polymer network was tuned by adjusting CyG to β-CD molar ratio. Structural characterization of the CDPC was performed using a combination of analytical techniques, including 1H NMR, 13C NMR, HSQC, DOSY NMR, FT-IR, and CHN elemental analysis. Compared to CDP, CDPC exhibited improved RES encapsulation efficiency, as demonstrated by phase solubility and encapsulation studies. The enhanced encapsulation is attributed to additional intramolecular interactions provided by CyG moieties. Dynamic light scattering revealed nanoscale polymer-RES complexes with average sizes of 4 nm for CDP/RES and 18 nm for CDPC/RES, while zeta potential values indicated that these complexes are neutral to slightly negatively charged. CDPC demonstrated intrinsic antioxidant activity, further enhanced upon RES encapsulation. Cytocompatibility assays confirmed that both CDP and CDPC were non-toxic to human chondrocytes. Confocal microscopy of FITC-labeled CDP and CDPC demonstrated effective internalization of these polymers by chondrocytes. Moreover, the CDP/RES and CDPC/RES complexes enhanced chondrocyte metabolic activity and extracellular matrix deposition, demonstrating their potential as carriers for drug delivery in cartilage tissue regeneration.
- 21 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessCyclodextrin-epichlorohydrin-cyanoguanidine polymer for resveratrol delivery to enhance human chondrocyte function in cartilage repair
Water-soluble β-cyclodextrin-epichlorohydrin polymers (CDP) are widely utilized for molecular encapsulation, drug delivery, and regenerative medicine. In this work, we present the synthesis of a novel polymer of this family, β-cyclodextrin-epichlorohydrin-cyanoguanidine polymer (CDPC). The primary objective was to evaluate its potential as an efficient carrier for the encapsulation of resveratrol (RES), with a particular focus on applications in cartilage repair. CDPC was synthesized by reacting β-cyclodextrin (β-CD) with epichlorohydrin in the presence of cyanoguanidine (CyG), a nitrogen-rich compound that remains non-protonated under physiological pH. The incorporation of CyG into the polymer network was tuned by adjusting CyG to β-CD molar ratio. Structural characterization of the CDPC was performed using a combination of analytical techniques, including 1H NMR, 13C NMR, HSQC, DOSY NMR, FT-IR, and CHN elemental analysis. Compared to CDP, CDPC exhibited improved RES encapsulation efficiency, as demonstrated by phase solubility and encapsulation studies. The enhanced encapsulation is attributed to additional intramolecular interactions provided by CyG moieties. Dynamic light scattering revealed nanoscale polymer-RES complexes with average sizes of 4 nm for CDP/RES and 18 nm for CDPC/RES, while zeta potential values indicated that these complexes are neutral to slightly negatively charged. CDPC demonstrated intrinsic antioxidant activity, further enhanced upon RES encapsulation. Cytocompatibility assays confirmed that both CDP and CDPC were non-toxic to human chondrocytes. Confocal microscopy of FITC-labeled CDP and CDPC demonstrated effective internalization of these polymers by chondrocytes. Moreover, the CDP/RES and CDPC/RES complexes enhanced chondrocyte metabolic activity and extracellular matrix deposition, demonstrating their potential as carriers for drug delivery in cartilage tissue regeneration.